BioRestorative Therapies, Inc. BRTX shares are trading higher Thursday after the company said it has engaged in licensing discussions with a undisclosed commercial regenerative medicine company.
What Happened: BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions with an regenerative medicine company related to its ThermoStem Metabolic Disease Program intellectual property.
Research conducted in collaboration with the University of Utah School of Medicine has demonstrated that certain stem cells with brown adipogenic potential could represent a new way of treating obesity and related metabolic disorders.
Currently, there is no guarantee that a license agreement will be made between the two companies.
Related Link: Candel Therapeutics’ CADL enLIGHTEN Discovery Platform Aims To Tackle Complexities Of Tumor Microenvironments
BRTX Price Action: At the time of writing, BioRestorative shares are trading 29% higher at $1.75 per data from Benzinga Pro.
Image: Image via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
